Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives Average Rating of “Hold” from Analysts

Artelo Biosciences, Inc. (NASDAQ:ARTL) has been given a consensus rating of “Hold” by the five ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $24.00.

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, December 29th. Maxim Group reissued a “hold” rating on shares of Artelo Biosciences in a research report on Wednesday, November 19th.

Artelo Biosciences Stock Performance

Artelo Biosciences stock opened at $1.71 on Friday. The company has a market capitalization of $3.45 million, a P/E ratio of -0.08 and a beta of 1.04. Artelo Biosciences has a fifty-two week low of $1.15 and a fifty-two week high of $28.60. The stock has a 50-day simple moving average of $1.64 and a 200-day simple moving average of $4.95.

Artelo Biosciences (NASDAQ:ARTL) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($3.97) EPS for the quarter, missing the consensus estimate of ($0.82) by ($3.15). As a group, analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.